<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7372203\results\search\testTrace\results.xml">
  <result pre="storm. Introduction Although the pathogenesis of COVID-19, the result of" exact="infection" post="with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is"/>
  <result pre="non-specific symptoms (i.e. malaise, fever, sore throat, dry cough), and" exact="treatment" post="is often symptomatic. Stage II is characterized by hyperresponsiveness"/>
  <result pre="harm. Whether such agents are beneficial in other stages of" exact="infection" post="remains a matter of study. Â Created with biorender.com."/>
  <result pre="T cells, develops later and contributes to both clearing of" exact="infection" post="and immunity against subsequent infection. Innate and adaptive immunity"/>
  <result pre="of anakinra and emapalumab, an anti-interferon (IFN)-Î³ antibody, in the" exact="treatment" post="of hyperinflammatory syndrome caused by the cytokine storm commenced"/>
  <result pre="patients [25]. The authors concluded that tocilizumab is an effective" exact="treatment" post="in severely ill COVID-19 patients. Tocilizumab was administered as"/>
  <result pre="ill patients is sarilumab (KefzaraÂ®), which is indicated for the" exact="treatment" post="of adult patients with moderately to severely active RA"/>
  <result pre="ill (i.e. requiring mechanical ventilation or high-flow oxygenation, or required" exact="treatment" post="in an intensive care unit) COVID-19 patients, but not"/>
  <result pre="in combination with or without an antiviral agent for the" exact="treatment" post="of COVID-19 (NCT04346147, NCT04320277, NCT04345289, NCT04321993). Notably, baricitinib is"/>
  <result pre="of Allergy and Infectious Diseasesâ€™ (NIAID) phase III adaptive COVID-19" exact="treatment" post="trial [41]. Currently, the National Institutes of Health (NIH)"/>
  <result pre="Panel recommends against the use of JAK inhibitors for the" exact="treatment" post="of COVID19 except in the context of a clinical"/>
  <result pre="Trial. This combination may be able to control the viral" exact="infection" post="as well as reduce the immune system reaction. Anti-tumor"/>
  <result pre="initiate anti-TNFÎ± therapy as early as possible [49], as delayed" exact="treatment" post="may limit the effectiveness of these agents. The potential"/>
  <result pre="more advanced stages. A Chinese study evaluating adalimumab in COVID-19" exact="infection" post="is underway (ChiCTR2000030089). A prospective, single center, phase II"/>
  <result pre="5Â days in addition to standard of care, or standard-of-care" exact="treatment" post="alone. Patients in the experimental arm who progress to"/>
  <result pre="virus clearance and acute lung injury, as well as ARDS" exact="treatment" post="[52], it is important that GM-CSF be investigated via"/>
  <result pre="evaluating the role of intravenous gimsilumab in the prevention and" exact="treatment" post="of ARDS and mortality in COVID-19 is underway (NCT04351243)."/>
  <result pre="convalescent plasma transfusion from patients who have recovered from the" exact="infection" post="with a high neutralizing antibody titer (NAT) may provide"/>
  <result pre="passive immunity that could be beneficial in the prevention of" exact="infection" post="or as a treatment strategy for patients with COVID-19"/>
  <result pre="be beneficial in the prevention of infection or as a" exact="treatment" post="strategy for patients with COVID-19 [63â€&quot;68]. Convalescent plasma has"/>
  <result pre="In a study of 93 patients with severe H1N1 2009" exact="infection" post="requiring intensive care, 20 (21.5%) of whom received convalescent"/>
  <result pre="onset of symptoms manifested better outcomes than those who received" exact="treatment" post="later in the disease course [63, 64, 69, 72]."/>
  <result pre="(NAT of 80â€&quot;480) in conjunction with continued methylprednisolone and antiviral" exact="treatment" post="[73]. Before transfusion, patients displayed continuously high viral load"/>
  <result pre="Before transfusion, patients displayed continuously high viral load despite antiviral" exact="treatment" post="for at least 10Â days. Plasma transfusion was administered"/>
  <result pre="95% CI 1.07â€&quot;4.32, pâ€‰=â€‰0.03). However, most patients received convalescent plasma" exact="treatment" post="at least 14Â days after symptom onset, further suggesting"/>
  <result pre="viral infections [78], including SARS, although the benefits of the" exact="treatment" post="were inconclusive and some cases of thromboembolic complications were"/>
  <result pre="use of commercially available IVIG (i.e. non-SARS-CoV-2-specific IVIG) for the" exact="treatment" post="of COVID-19, in part because the current IVIG preparations"/>
  <result pre="do not recommend the routine use of systemic corticosteroids for" exact="treatment" post="of viral pneumonia unless indicated for another reason, such"/>
  <result pre="involving mechanically ventilated adult patients with ARDS with confirmed COVID-19" exact="infection" post="has commenced (NCT04325061). Compared with methylprednisolone, dexamethasone has less"/>
  <result pre="two of whom received methylprednisolone. Wu et al. showed that" exact="treatment" post="with methylprednisolone decreased the risk of death (HR 0.38,"/>
  <result pre="reducingÂ viral multiplication and modulating host immune response against viral" exact="infection" post="[100]. They consist of the ubiquitous Î± and Î²"/>
  <result pre="IFNsÂ are released by plasmacytoid dendritic cellsÂ during a viral" exact="infection" post="[100]. IFN treatment has been studied against MERS-CoV and"/>
  <result pre="by plasmacytoid dendritic cellsÂ during a viral infection [100]. IFN" exact="treatment" post="has been studied against MERS-CoV and SARS-CoV [78]. Due"/>
  <result pre="COVID-19 (NCT04293887, NCT04350281). Clinical trials evaluating subcutaneous peginterferon lambda-1a for" exact="treatment" post="(e.g. NCT04354259, NCT04388709) and postexposure prophylaxis (e.g. NCT04344600) of"/>
  <result pre="(e.g. NCT04354259, NCT04388709) and postexposure prophylaxis (e.g. NCT04344600) of SARS-CoV-2" exact="infection" post="are also underway. A multicenter, randomized, prospective study on"/>
  <result pre="the combination group had a significantly shorter median time from" exact="treatment" post="initiation to negative nasopharyngeal swab (7Â days vs. 12Â"/>
  <result pre="inflammation and lung pathology and increased mouse survival after SARS-CoV" exact="infection" post="[113]. OverexpressionÂ orÂ underexpression of the MyD888 gene can"/>
  <result pre="underexpression of the MyD888 gene can increase the vulnerability to" exact="infection" post="and mortality from SARS-like coronaviruses [114, 115]. While statins"/>
  <result pre="a multihospital retrospective cohort study of 2746 patients describing the" exact="prevalence" post="of myocardial injury in COVID-19 patients, Lala et al."/>
  <result pre="having no disease symptoms in the entire study duration while" exact="testing" post="positive on PCR (unadjusted odds ratio 2.91, 95% CI"/>
  <result pre="Italian population-based caseâ€&quot;control study of 6272 patients with confirmed SAR-CoV-2" exact="infection" post="revealed that there is no evidence that the use"/>
  <result pre="COVID-19, severity of the clinical manifestations, or the course of" exact="infection" post="[125]. While the use of an ACEi or ARB"/>
  <result pre="COVID-19 than in controls, this was due to the higher" exact="prevalence" post="of cardiovascular disease in these patients. Both of these"/>
  <result pre="and ARB is not associated with an increased risk of" exact="infection" post="with SARS-CoV-2. Thus, these agents should not be discontinued,"/>
  <result pre="therapy to provide antibacterial and potential immunomodulatory effects in the" exact="treatment" post="of viral respiratory tract infections, including influenza [133, 135],"/>
  <result pre="imply that post-exposure prophylaxis is not effective in preventing symptomatic" exact="infection" post="among patients who are exposed to known COVID-19-positive infections."/>
  <result pre="which evaluated the safety and effectiveness of hydroxychloroquine for the" exact="treatment" post="of COVID-19 in hospitalized adults, was halted by the"/>
  <result pre="Thus, the high-dose regimen should not be recommended for the" exact="treatment" post="of severe COVID-19, particularly in patients also receiving azithromycin"/>
  <result pre="a potent oral anti-inflammatory medication that is indicated for the" exact="treatment" post="of gout, familial Mediterranean fever, and pericarditis (off-label) [151]."/>
  <result pre="newly diagnosed patients and will assess the impact of colchicine" exact="treatment" post="on rates of hospitalization or death from the syndrome"/>
  <result pre="underlying myocardial dysfunction Use caution in elderly patients; may increase" exact="infection" post="risk Sargramostim 125Â Î¼g bid for 5Â days Nebulized"/>
  <result pre="to corticosteroids or any component of the formulation, systemic fungal" exact="infection" post="SubstrateÂ of CYP3A4 and P-gp/ABCB1. Live or attenuated virus"/>
  <result pre="to corticosteroids or any component of the formulation, systemic fungal" exact="infection" post="CYP3A4 substrate Live or attenuated virus vaccines (if using"/>
  <result pre="be continued in COVID-19 patients with asthma and COPD Corticosteroid" exact="treatment" post="in pregnant women should be individualized; benefits should be"/>
  <result pre="adaptive immune responses have been demonstrated with Hemophilus influenzae respiratory" exact="infection" post="[160]. Furthermore, ILC2s, despite their scarcity, are the dominant"/>
  <result pre="well-established safety profile and has been used orally as a" exact="treatment" post="for allergic rhinitis in Japan for the past 20Â"/>
  <result pre="in the pipeline, more options may become available for the" exact="treatment" post="of COVID-19. Recent studies have demonstrated that hydroxychloroquine and"/>
  <result pre="coronavirus disease 2019 pneumonia in WuhanChina JAMA Intern Med2020180711110.1001/jamainternmed.2020.0994 7.MahallawiWHKhabourOFZhangQMakhdoumHMSulimanBAMERS-CoV" exact="infection" post="in humans is associated with a pro-inflammatory Th1 and"/>
  <result pre="for non-organ-specific autoimmune diseasesBest Pract Res Clin Rheumatol201226115716510.1016/j.berh.2012.01.00122424201 25.XuXHanMLiTet al.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc Natl Acad Sci"/>
  <result pre="Commission and State Administration of traditional Chinese medicine. Diagnosis and" exact="treatment" post="protocol for novel coronavirus pneumonia. From China consulate website."/>
  <result pre="From China consulate website. https://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf. Accessed 20 Mar 2020. 27.LuoPLiuYQiuLLiuXLiuDLiJTocilizumab" exact="treatment" post="in COVID-19: a single center experienceJ Med Virol202010.1002/jmv.2580132584483 28.AlbericiFDelbarbaEManentiCet"/>
  <result pre="trial for the efficacy and safety of tocilizumab in the" exact="treatment" post="of new coronavirus pneumonia (COVID-19). https://www.chictr.org.cn/showprojen.aspx?proj=49409. Accessed 15 June"/>
  <result pre="two case reportsInt J Antimicrob Agents202010.1016/j.ijantimicag.2020.10602332450201 36.RichardsonPGriffinITuckerCet al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet202039510223e30e3110.1016/S0140-6736(20)30304-432032529 37.Olumiant [package insert]. Indianapolis,"/>
  <result pre="Apr 2020. 42.National Institutes of Health. Coronavirus disease 2019 (COVID-19)" exact="treatment" post="guidelines. https://www.covid19treatmentguidelines.nih.gov/). Accessed 11 May 2020. 43.NIH clinical trial"/>
  <result pre="treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/). Accessed 11 May 2020. 43.NIH clinical trial" exact="testing" post="antiviral remdesivir plus anti-inflammatory drug baricitinib for COVID-19 begins"/>
  <result pre="therapeutic strategy?Mol Cell Pediatr2016312910.1186/s40348-016-0055-527480877 52.HeroldSHoegnerKVadÃ¡szIet al.Inhaled granulocyte/macrophage colony-stimulating factor as" exact="treatment" post="of pneumonia-associated acute respiratory distress syndromeAm J Respir Crit"/>
  <result pre="Sci Rev202010.1093/nsr/nwaa041 60.ZhangWZhaoYZhangFet al.The use of anti-inflammatory drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): the"/>
  <result pre="May 2020. 63.BlochEMBaileyJATobianAARDeployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19J Clin Investig202013062757276510.1172/JCI13874532254064 64.TiberghienPde LambalarieXMorelPet al.Collecting and evaluating"/>
  <result pre="69.SooYOChengYWongRet al.Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone" exact="treatment" post="in SARS patientsClin Microbiol Infect200410767667810.1111/j.1469-0691.2004.00956.x15214887 70.ArabiYBalkhyHHajeerAHet al.Feasibility, safety, clinical,"/>
  <result pre="respiratory syndrome coronavirus infection: a study protocolSpringerplus2015470910.1186/s40064-015-1490-926618098 71.HungIFToKKLeeCKet al.Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
  <result pre="al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
  <result pre="LLC; 2007.https://www.fda.gov/media/83304/download. Accessed 7 May 2020. 78.StockmanLJBellamyRGarnerPSARS: systemic review of" exact="treatment" post="effectsPLoS Med20063e34310.1371/journal.pmed.003034316968120 79.UmapathiTKorACVenketasubramanianNet al.Large artery ischaemic stroke in severe"/>
  <result pre="with severe acute respiratory syndromePostgrad Med J200581e310.1136/pgmj.2004.03004915937197 81.NguyenAAHabiballahSBPlattCDGehaRSChouJSMcDonaldDRImmunoglobulins in the" exact="treatment" post="of COVID-19 infection: proceed with caution!Clin Immunol202021610845910.1016/j.clim.2020.10845932418917 82.GaleottiCKaveriSVBayryJIVIG-mediated effector"/>
  <result pre="2019 (COVID-19)Crit Care Med2020486e440e46910.1097/CCM.000000000000436332224769 86.RussellCDMillarJEBaillieJKClinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 87.MontonCEwigSTorresAEl-EbiaryMFilellaXRaÃ±Ã³AXaubetARole of glucocorticoids on inflammatory"/>
  <result pre="use of corticosteroids for 2019-nCoV pneumoniaLancet202039568368410.1016/S0140-6736(20)30361-532122468 92.VillarJConfalonieriMPastoresSMeduriGUmbertoMDRationale for prolonged corticosteroid" exact="treatment" post="in the acute respiratory distress syndrome caused by coronavirus"/>
  <result pre="disease 2019Crit Care Explor202024e011110.1097/CCE.000000000000011132426753 93.RodrigoCLeonardi-BeeJNguyen-Van-TamJLimWSCorticosteroids as adjunctive therapy in the" exact="treatment" post="of influenzaCochrane Database Syst Rev201610.1002/14651858.CD010406.pub226950335 94.ArabiYMMandourahYAl-HameedFSindiAAAlmekhlafiGAHusseinMAet al.Corticosteroid therapy for"/>
  <result pre="Med2018197675776710.1164/rccm.201706-1172OC29161116 95.World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected. Interim guidance. 13"/>
  <result pre="complications of COVID-19. https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf. Accessed 20 June 2020. 98.VillarJFerrandoCMartÃ­nezDet al.Dexamethasone" exact="treatment" post="for the acute respiratory distress syndrome: a multicentre, randomised"/>
  <result pre="Respir Med20208326727610.1016/S2213-2600(19)30417-532043986 99.WangYJiangWHeQet al.Early, low-dose and short-term application of corticosteroid" exact="treatment" post="in patients with severe COVID-19 pneumonia: single-center experience from"/>
  <result pre="experience from Wuhan, ChinamedRxiv202010.1101/2020.03.06.2003234232607523 100.SallardELescureFXYazdanpanahYMentreFPeiffer-SmadjaNType 1 interferons as a potential" exact="treatment" post="against COVID-19Antiviral Res202017810479110.1016/j.antiviral.2020.10479132275914 101.Lokugamage KG, Hage A, Schindewolf C,"/>
  <result pre="Infect Dis201414111090109510.1016/S1473-3099(14)70920-X25278221 105.ChenLShiMDengQet al.A multi-center randomized prospective study on the" exact="treatment" post="of infant bronchiolitis with interferon Î±1b nebulization [published correction"/>
  <result pre="al.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: an open-label,"/>
  <result pre="with COVID-19: an open-label, randomised, phase 2 trialLancet2020395102381695170410.1016/S0140-6736(20)31042-432401715 107.ZhouQChenVShannonCPet al.Interferon-Î±2b" exact="treatment" post="for COVID-19Front Immunol202011106110.3389/fimmu.2020.0106132574262 108.Dashti-KhavidakiSKhaliliHConsiderations for statin therapy in patients"/>
  <result pre="coronavirus infectionmBio201563e00638-1510.1128/mBio.00638-1526015500 115.SheahanTMorrisonTEFunkhouserWet al.MyD88 is required for protection from lethal" exact="infection" post="with a mouse-adapted SARS-CoVPLoS Pathog2008412e100024010.1371/journal.ppat.100024019079579 116.YuanXDengYGuoXShangJZhuDLiuHAtorvastatin attenuates myocardial remodeling"/>
  <result pre="of ARBs, ACEIs and statins on clinical outcomes of COVID-19" exact="infection" post="among nursing home residentsJ Am Med Dir Assoc202010.1016/j.jamda.2020.06.01832674818 119.ChangYWeiWAngiotensin"/>
  <result pre="susceptibility to and severity of COVID-19JAMA202010.1001/jama.2020.1140132558905 127.Bermejo-MartinJFKelvinDJEirosJMet al.Macrolides for the" exact="treatment" post="of severe respiratory illness caused by novel H1N1 swine"/>
  <result pre="monocytic cell lineJ Microbiol Immunol Infect20195287287910.1016/j.jmii.2019.10.00131759853 131.AbramsEMRaissyHHEmerging therapies in the" exact="treatment" post="of early childhood wheezePediatr Allergy Immunol Pulmonol201932788010.1089/ped.2019.104331508261 132.ArabiYMDeebAMAl-HameedFet al.Macrolides"/>
  <result pre="efficacy of oseltamivir-azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09" exact="infection" post="complications and rapidity of symptoms reliefExpert Rev Respir Med202014553354110.1080/17476348.2020.173018032053044"/>
  <result pre="epithelial cellsEur Respir J20154542843910.1183/09031936.0010201425359346 135.LeeNWongCKChanMCWet al.Anti-inflammatory effects of adjunctive macrolide" exact="treatment" post="in adults hospitalized with influenza: a randomized controlled trialAntivir"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
  <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progressionJ Antimicrob Chemother20207571667167010.1093/jac/dkaa11432196083 141.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria to autoimmunityClin"/>
  <result pre="Metab Toxicol201511111781179410.1517/17425255.2015.107639126239119 153.GendelmanOAmitalHBragazziNLWatadAChodickGContinuous hydroxychloroquine or colchicine therapy does not prevent" exact="infection" post="with SARS-CoV-2: insights from a large healthcare database analysisAutoimmun"/>
  <result pre="migration, resulting in diminished T cell responses upon respiratory virus" exact="infection" post="in miceJ Clin Investig2011121124921493010.1172/JCI5977722105170 159.TrabanelliSChevalierMFMartinez-UsatorreAet al.Tumour-derived PGD2 and NKp30-B7H6"/>
 </snippets>
</snippetsTree>
